Long-term ALS survival benefit with CNM-Au8 seen in trial analyses

Innovating Clinical Trials for Amyotrophic Lateral Sclerosis

Clene Releases Significant Long-Term Survival Improvement Data from ALS Trial

A Mechanism Underpinning the Bioenergetic Metabolism‐Regulating Function of Gold Nanocatalysts - Wang - Small - Wiley Online Library

Frontiers New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022

Clene: Still in the Running for ALS

Clene: Still in the Running for ALS

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls -September 25, 2023 at 07:01 am EDT

Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. - Abstract - Europe PMC

Neuromuscular Notes: New and Emerging Therapies in ALS - Practical Neurology

TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia - ScienceDirect

Early CNM-Au8 Treatment Leads to Significant Survival Benefit in Study, Lower Mortality Risk in ALS Patients Assigned CNM-Au8 vs Placebo

img_001.jpg